Scale-up and optimization of the synthesis of dual CBP/BRD4 inhibitor ISOX-DUAL

Org Biomol Chem. 2022 May 18;20(19):4021-4029. doi: 10.1039/d2ob00609j.

Abstract

ISOX-DUAL is a dual inhibitor of CBP/p300 (IC50 = 0.65 μM) and BRD4 (IC50 = 1.5 μM) bromodomains, and a useful chemical probe for epigenetic research. Aspects of the published synthetic route to this compound and its analogues are small-scale, poor-yielding or simply unamenable to scale-up without optimization. Herein we describe the development of a refined synthesis that circumvents the challenges of the original report, with notable improvements to several of the key synthetic transformations. Moreover, a general Suzuki Miyaura protocol for the late stage installation of alternative dimethyl-isoxazole acetyl-lysine (KAc) binding motifs is presented.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle Proteins / metabolism
  • Isoxazoles / chemistry
  • Lysine
  • Nuclear Proteins* / chemistry
  • Protein Domains
  • Transcription Factors* / chemistry

Substances

  • Cell Cycle Proteins
  • Isoxazoles
  • Nuclear Proteins
  • Transcription Factors
  • Lysine